GLP-1 Bridge Claim Rejected? Cash-Pay Options and 11 Code Paths

By the WPG Research Team · Last verified: August 5, 2026
Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.
Some links below are affiliate links. They never change your price, and they never change which route we say wins. Advertising disclosure.

If your GLP-1 Bridge claim was rejected and you're comparing cash-pay options, read this before you spend a dollar.

Here's what almost nobody tells you at the counter: when the Medicare GLP-1 Bridge requires prior authorization, the first correctly routed pharmacy claim must come back rejected before your prescriber submits the PA. Code 75 is the expected PA trigger. Other codes can mean a Medicare-number mismatch, the wrong product or package, a refill-timing problem, an ineligible plan type, or a real coverage block. The code decides which one you have—not the word rejected by itself. (CMS reject-code tool; official PA form)

If yours turns out to be a real dead end, current published self-pay prices for the drugs the Bridge covers start at $149 per monthly supply and commonly reach $449 under manufacturer Journey terms. Miss the Zepbound 45-day refill condition and some doses rise to $699. Care fees, supplies, taxes, and clinical eligibility can change the total. (NovoCare prices; LillyDirect Zepbound; LillyDirect Foundayo)

But first we're going to show you how to tell which situation you're actually in. For someone comparing a standard 28-day Wegovy pen route, fixing the $50 Bridge instead of paying $349 cash can preserve about $3,887 over 13 fills. That's real money for one code and one phone call.

Start here: what did they actually tell you?

Best for: People enrolled in eligible Medicare Part D drug coverage who already have a rejected Bridge pharmacy claim.
Not for: People still figuring out whether they qualify, people without Medicare drug coverage, or anyone asking which medication is medically right for them.

Bottom line: Get the exact reject code before you pay cash. A code-75 rejection may be the step that starts your approval; a code-65, code-70, identity, timing, or technical rejection follows a different path. Only move to cash pay after the Bridge problem is identified and the $50 route is truly unavailable.

Was your GLP-1 Bridge claim actually denied—or did it trigger the prior authorization?

A pharmacy rejection and a prior-authorization denial are two different things. CMS requires a denied pharmacy claim through the Bridge BIN and PCN before a prescribing clinician submits the Bridge PA. But not every first rejection is code 75, and not every rejection is harmless—the exact code and full message tell you what happened. (CMS PA form)

We want to be blunt about this, because one word at the pharmacy counter is making people abandon a route that could still cost $50.

The Bridge sits outside the normal Medicare Part D payment flow. It uses its own central processor, claim-routing numbers, and prior-authorization process. When a correctly routed claim needs clinical paperwork, the system returns code 75: prior authorization required. That is not a verdict on you. It is the event that lets the prescriber send the form.

But rejected is also the word used for identity errors, ineligible NDCs, early refills, invalid prescriber information, excluded plan types, and other problems. So this page will not tell you that every rejection is routine. It will tell you what yours means.

The three different things people call “rejected”

1. The required PA-trigger rejection. Code 75. The Bridge claim reached the right processor and now needs the prescriber's clinical form.

2. A claim-processing or routing rejection. The claim went to the wrong payer, used the wrong identity information, requested the wrong NDC or quantity, arrived too early, or failed another transaction rule.

3. An actual Bridge PA denial. This happens after the prescribing clinician submits the clinical information and the central processor reviews it. CMS mails the patient a decision and sends the decision to the prescriber through ePA or fax.

If no PA decision has been issued, do not guess which category you are in. Get the code and the full message.

What people are running into

These are real, public process comments from Medicare beneficiaries. They show the friction people are describing; they are not evidence that you qualify, that your claim will be approved, or that any treatment is right for you.

“Help help I keep getting rejected but my provider never gets a PA.”
— public comment, r/medicare

“The pharmacy sent the prescription to the Part D insurer instead of the Medicare Bridge Program.”
— public post, r/medicare

“I fit all the criteria. Did someone do something wrong?”
— Jayne Marie Lilly, public comment on Medicare Rights Center, July 10, 2026

Notice what all three have in common. The person still needed to identify the processing path—not assume the word rejected settled the question.

Now here's the flip side, and it's worth reading if you're feeling defeated:

“July 2, got a text from CVS saying my Rx was ready with a copay of $50.”
— Julie, public comment on Medicare Rights Center, July 8, 2026

Her experience is not a promise about yours. It shows why the first job is finding the stalled handoff rather than immediately replacing the whole route.

Not sure which of the three you got?
Decode my Bridge rejection → Answer a few administrative questions about what the pharmacy told you. No account, no email, and no Medicare number.

What does your Medicare GLP-1 Bridge reject code mean?

The NCPDP reject code—not the pharmacist's one-word summary—tells you what actually happened. Code 75 means prior authorization is required. Code 70 means the submitted NDC is not eligible for the Bridge. Code 65 means “patient not covered,” but six different CMS messages can sit underneath it and lead to different next steps. (CMS reject-code tool)

This is the part that saves people money, so we built it as a lookup table.

CMS publishes the raw code list for pharmacy staff. It is five pages of technical language written for people who process claims for a living. What follows is our own regrouping of that information—sorted by who has to fix it, which is the question you actually need answered.

The Medicare GLP-1 Bridge rejection decoder

Green means CMS gives a defined correction or next step and you should not be shopping cash prices yet.
Amber means you need the complete message, timing, or record status before deciding.
Red means that specific transaction, route, or entity is blocked. Red on a prescriber or pharmacy does not automatically mean red on you.

That color system is ours. CMS does not publish it. We built it because “code 543” tells you nothing about whether to reach for your credit card.

Code 75: prior authorization required

This is the big one, and it is green.

Code 75 is the system saying “we need the prescriber's paperwork.” The official Bridge PA form says a denied pharmacy claim must be submitted through BIN 028918 and PCN MEDDGLP1BR before the prescribing clinician submits the PA.

Read that again if you need to. For the PA route, the rejected claim is a required step. It is not approval, but it is not a final denial either.

What should happen next: the pharmacy transmits the PA request electronically or by fax, typically within 24 to 72 hours. The prescribing clinician completes and submits it. After approval, the pharmacy reruns the claim if its system does not automatically receive the result. (CMS provider FAQ; CMS pharmacy FAQ)

What can happen instead: the request is never manually sent, it lands in an electronic queue nobody checks, or the office searches only its fax inbox.

Code 70: the product, not the person

This one gets misreported, and it matters.

Code 70 means the NDC the pharmacy submitted is not eligible for the Bridge. CMS's direction is to rewrite or resubmit for an eligible NDC when medically appropriate. It does not, by itself, say that the patient failed the clinical criteria.

A prominent avoidable example is Zepbound. The Bridge covers the Zepbound KwikPen only. Single-dose vials and single-dose pens are not included. A claim for an excluded formulation can reject even when the patient's clinical information has never been reviewed.

The Bridge currently covers:

• Wegovy injections and tablets, including Wegovy HD
• Zepbound KwikPen only
• Foundayo tablets

The Bridge does not list Ozempic, Mounjaro, Rybelsus, Saxenda, Zepbound single-dose vials, Zepbound single-dose pens, or compounded products as covered Bridge drugs. (CMS covered products and NDCs)

The next move is not “switch yourself.” It is: confirm the exact drug, formulation, NDC, and prescription with the prescriber and pharmacy.

Code 65: never accept this one without the full message

Code 65 reads as “patient is not covered,” which sounds final. It is not one thing. It is six.

Reason three is worth understanding, because people misread it. In 2026, CMS reviews whether you received Zepbound, Mounjaro, Foundayo, Rybelsus, Ozempic, Wegovy, Saxenda, Victoza, or Trulicity through Part D during calendar year 2026. CMS has not yet announced the lookback period it will use in 2027. (CMS Part D FAQ)

So when someone tells you “code 65,” the only correct response is: “What's the full message?”

Quantity, timing, and prescriber codes

These are boring. That is good news. Most have an operational next step.

Codes 76 and E7 mean the requested days supply, strength, quantity, or package does not line up. The Bridge covers one 28-day or 30-day monthly supply per fill—not 60-day, 90-day, partial, or transition fills.

Code 79 means refill too soon. CMS's reject-code tool says the pharmacy should resubmit after more than 75% of the days-supply period has elapsed. Ask for the exact eligible rerun date instead of guessing.

Codes 81, 82, 83, and RK are different. CMS lists no resolution for the submitted transaction when a claim is outside the timely-filing period, post-dated, a duplicate paid/captured claim, or an unsupported partial fill. That is red for that transaction—not a finding that you failed the Bridge's clinical rules. Ask the pharmacy to explain what happened and whether any separate, valid current claim remains to be submitted.

Codes 25, 42, 56, 71, and 619 point to missing, invalid, inactive, or unmatched prescriber information. The office and pharmacy need to resolve the identifier—not send you shopping for another drug before they try.

Code 543 is specifically a foreign prescriber identifier. Codes 929, 930, A1, and A2 identify a precluded, sanctioned, deceased, or otherwise blocked prescriber or pharmacy. Resubmitting through the same blocked entity will keep failing. You need an eligible replacement. That is red for that entity—not automatically red for you.

Source note: The code meanings above come from the CMS Medicare GLP-1 Bridge Pharmacy NCPDP Reject Code Tool dated June 2026. The plain-English wording, owner column, and green/amber/red status are Weight Loss Provider Guide's original editorial classification.

What should you say to the pharmacy right now?

Ask for five specific facts: the exact reject code, the full message, which payer received the claim, the BIN and PCN used, and whether the PA request was transmitted. Without those, “Medicare rejected it” is not enough information to know whether the fix takes five minutes or whether the route is truly blocked.

Most pharmacists can see the transaction details. The problem is that almost nobody knows to ask for all five.

The five things to write down

1. The reject code. A number or short letter-number combination.
2. The full message. Not the summary. The actual text attached to the code.
3. Which payer received the claim—the Bridge or your regular Part D plan?
4. The BIN and PCN used. The Bridge uses BIN 028918 and PCN MEDDGLP1BR.
5. Whether the pharmacy transmitted a PA request to the prescriber—and when.

BIN and PCN are electronic routing identifiers. Think of them as the address that tells the pharmacy system where the claim goes.

Say this, word for word

“I'm trying to run this through the Medicare GLP-1 Bridge for weight management. Can you tell me the exact NCPDP reject code and the full message? Can you confirm whether the claim went to the Bridge or my Part D plan, and which BIN and PCN you used? If it came back as code 75, could you please send the prior-authorization request to my prescriber and tell me when it was sent?”

That's it. Read it off your phone if you want. Nobody will think less of you.

If the pharmacist is not sure, CMS publishes a pharmacy-only Bridge Help Desk at 844-673-0910 for claim-submission questions and submitted-claim status. That number is for the pharmacy, not a substitute for beneficiary support. It is fair to ask the pharmacist to use it. (CMS pharmacy FAQ)

Five answers you should not accept as final

• “It's not covered.”
• “Medicare denied it.”
• “You're not eligible.”
• “Your doctor has to fix it.”
• “The system won't take it.”

Every one of those is a summary, not an answer. Each one still needs the code, the full message, the payer route, and the next owner. Politely ask again.

A Medicare Rights Center commenter described a pharmacy refusing to submit because the patient had no additional condition even though the patient reported a starting BMI above 35. CMS's official criteria include a BMI-at-initiation pathway of 35 or higher without an added condition. That public comment does not prove what happened in that person's private record, but it shows exactly why asking for the code and CMS rule matters. (CMS provider criteria)

Going to call them back?
Print my pharmacy call sheet → A one-page checklist with blanks for the code, message, payer, BIN, PCN, transmission date, and who you spoke to. Free, no signup.

Did your pharmacy send the claim to the wrong place?

The Medicare GLP-1 Bridge runs through a central processor outside the normal Part D payment flow, and CMS does not require a Part D denial first. A prescriber can direct the pharmacy to send a potentially eligible weight-management claim straight to the Bridge using its dedicated BIN and PCN. (CMS pharmacy FAQ)

This is one of the simplest failures to correct—and public early-program reports show that it is happening.

Your pharmacy processes Medicare drug claims through Part D every day. The Bridge is different. CMS uses Humana as the central processor for prior authorization, claim adjudication, and pharmacy payment, and the claim is routed with BIN 028918 / PCN MEDDGLP1BR.

If the pharmacy ran a weight-management prescription through your normal Part D plan instead, the Part D response does not tell you what the Bridge would decide. The claim needs to reach the right processor before anyone can interpret the result.

Why Humana may appear even when Humana is not your plan

CMS uses Humana as the Bridge central processor. That means a Bridge transaction, prior-authorization communication, or claim-status discussion may identify Humana even when your personal Part D plan is issued by another company. Confirm that the communication actually concerns the Medicare GLP-1 Bridge and read the stated reason; do not assume “Humana” automatically means the claim went to the wrong insurer.

Bridge vs. Part D: what's actually different

That last distinction matters. The Bridge has a correction-and-resubmission path, not a formal appeal. Part D keeps its normal coverage-determination and appeal process.

How to get the claim re-routed

Ask the pharmacy to submit the weight-management claim to BIN 028918 / PCN MEDDGLP1BR. CMS recommends that the prescriber include diagnosis information and an annotation directing the pharmacy to the Bridge, but CMS also says neither item is required for the Bridge to process a claim.

Do not pay the cash price and assume the Bridge will reimburse you later. CMS says the central processor accepts electronic pharmacy claims—not paper claims or direct member reimbursement requests.

Internal next step: See the complete Medicare GLP-1 Bridge paperwork process.

What does your prescriber's office have to do—and how long should it take?

After the pharmacy determines that Bridge prior authorization is required, it typically transmits the PA request to the prescriber within 24 to 72 hours. CMS says the approval or denial is mailed to the patient and sent to the prescriber through the ePA portal or fax within 72 hours after submission. (CMS provider FAQ; CMS pharmacy FAQ)

There are two different clocks here. Mixing them together is how people call too early, wait too long, or think nothing happened.

Day 0—the pharmacy runs the claim

Write down:

• The date and time
• The code
• The full message
• Which payer received it
• The BIN and PCN
• Whether the pharmacy transmitted the PA request

This is your paper trail. You'll want it.

Hours 24 to 72—the pharmacy-to-prescriber handoff

The PA request may land in the prescriber's electronic queue or fax inbox. Call the office and ask staff to check both. Use the words “Medicare GLP-1 Bridge prior-authorization request from the pharmacy.” That is specific enough to search.

Do not start shopping cash prices just because the office has not seen it during this normal handoff window.

After 72 hours with no request

The prescriber does not have to wait forever for the pharmacy transmission. CMS says that once the denied Bridge pharmacy claim exists, the prescribing clinician can download the official form and submit it directly by electronic prior authorization or fax.

The official fax number on the CMS form is 1-800-530-2404.

Only a prescribing clinician can submit the Bridge PA. Do not fax your own medical information to a number you found online or email protected information to the general CMS mailbox.

Try this on the phone:

“The pharmacy already submitted the claim to the Medicare GLP-1 Bridge through BIN 028918 and PCN MEDDGLP1BR, and it came back needing prior authorization. Could someone check the electronic PA queue and fax inbox? If nothing arrived, CMS says the prescribing clinician can download and submit the Bridge form after the denied pharmacy claim.”

After 72 hours from PA submission

CMS says the decision is sent to the prescriber by ePA or fax and mailed to the patient within 72 hours of submission. The prescriber's electronic or faxed result may arrive before the patient's paper letter is delivered.

If the prescriber has no result after that window, the Medicare GLP-1 Bridge Call Center is 855-273-0102, Monday through Friday, 8 a.m. to 7 p.m. Eastern. CMS describes that number as support for prescriber questions about the PA process or PA status. Beneficiaries can call 1-800-MEDICARE for Medicare eligibility and coverage help.

If the PA is approved and the pharmacy does not use an ePA system that receives the decision automatically, the pharmacy may need to rerun the claim before it processes at $50.

The hard part: there is no formal appeal inside the Bridge

We're going to say this clearly because “resubmission” and “appeal” are not the same thing.

CMS states there is no appeals process under the Medicare GLP-1 Bridge.

A prescribing clinician may resubmit the PA when the original form contained incorrect information or when updated or additional information is available. That is narrower than an unlimited retry right: an unchanged denial does not create a free-standing right to keep resubmitting the same information.

And there is a second door. The Bridge does not change your Part D appeal rights. If the prescription belongs under the basic Part D benefit, the plan must follow its coverage-determination, formulary-exception, and appeal obligations.

If your prescriber's office will not do the paperwork

It happens. Some practices are swamped. Some do not manage obesity medication. Some have not learned the Bridge workflow.

That is a real problem, because only a prescribing clinician can submit the form. But CMS says the prescriber does not need to be enrolled in Medicare to prescribe an eligible product or submit the Bridge PA. The prescriber must not be on the CMS Preclusion List.

One current option worth knowing about is Sesame. Its Medicare-specific weight-loss page says the provider confirms Medicare coverage and submits the prior authorization. The Success by Sesame membership starts at $59 per month, and an approved Bridge medication carries the separate $50 pharmacy copay. At the published starting membership price, that is a starting combined recurring amount of $109 per month—if the $59 plan applies to you and CMS approves the medication. (Sesame Medicare program)

Be clear-eyed about it: that is a recurring care fee for paperwork and ongoing care your current prescriber may be willing to handle without a separate membership. If your own office is willing and able, use them. Sesame earns its fee when the existing prescriber route is genuinely stuck and the service is available for your situation.

Affiliate disclosure: Weight Loss Provider Guide may earn a commission if you use the Sesame link below. That does not change the price you pay or our rule that your current prescriber wins when they will complete the Bridge process without an added membership.

Prescriber's office will not handle the Bridge paperwork?
See whether a Sesame provider can handle your Bridge prior authorization → (affiliate link)
A provider visit does not guarantee medical eligibility, Bridge eligibility, or approval. Confirm the current membership price and availability before enrolling.

Could regular Part D cover this instead?

Some GLP-1 prescriptions belong under the ordinary Part D benefit rather than the Bridge. Type 2 diabetes, moderate-to-severe obstructive sleep apnea, and certain noncirrhotic MASH cases are Bridge exclusions even when the current plan does not cover the requested GLP-1; Wegovy prescribed to reduce major cardiovascular events must also be routed to Part D. (CMS provider FAQ; CMS Part D FAQ)

This is worth ten minutes before you pay cash, because Part D has appeal rights the Bridge does not.

Conditions that route through Part D, not the Bridge

CMS says a beneficiary is not Bridge-eligible for the requested drug when the person has:

• Type 2 diabetes
• Moderate-to-severe obstructive sleep apnea
• Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis

That exclusion applies even when the person's current Part D plan does not cover a GLP-1 for that condition. In that frustrating situation, the request still belongs in Part D, where the plan must use its existing formulary-exception and appeal process. The Bridge is not a substitute payer for a Part D-coverable indication.

For cardiovascular disease, the question is the prescription's purpose. The Bridge form does not require the clinician to attest that the patient has no established cardiovascular disease. But if Wegovy is being prescribed to reduce the risk of major adverse cardiovascular events—even if weight reduction is also a goal—the request belongs in Part D.

Why a higher Part D amount can still be the better annual deal

The Bridge is $50 per fill, which sounds unbeatable. But the $50 does not count toward your Part D deductible or the $2,100 Part D out-of-pocket cap for 2026. Covered Part D out-of-pocket spending does. (Medicare 2026 Part D costs)

So a higher Part D charge can still produce a lower total annual drug bill when you take several expensive covered prescriptions or expect to reach the cap. The answer depends on your plan, deductible, other prescriptions, and where you are in the year.

Your plan's member-services team can explain its own math. A free State Health Insurance Assistance Program counselor can help you compare routes through SHIP.

No provider link here. If this section is you, use the Part D process. That's the answer.

When should you stop trying to fix the rejection and start comparing cash-pay options?

Cash pay makes sense after you have ruled out the required PA trigger, a correctable pharmacy or prescription error, a routing problem, an unresolved code-65 message, and a viable Part D route. Until then, paying cash means spending at least $99 more per monthly supply—and sometimes far more—for a problem that may still have a defined fix.

Here's the honest threshold, using the same colors from the decoder.

🟢 Green—do not pay cash yet

You're here if you got:

• Code 75
• An MBI, name, or date-of-birth mismatch
• A quantity or days-supply problem
• A refill-too-soon message
• A technical processing error
• A code 70 where the prescriber may choose an eligible product or NDC

These have defined next steps. Make the calls. Work the correct clock.

🟡 Amber—get more information first

You're here if:

• You got code 65 without the full message
• The pharmacy says “ineligible” but cannot produce a code
• The PA request is still inside the pharmacy-to-prescriber window
• The PA was submitted and the 72-hour decision window has not passed
• The status record conflicts with your Medicare information
• You may have a Part D-coverable indication

You do not have enough information to abandon the $50 route yet.

🔴 Red—cash-pay comparison makes sense now

You're here if:

• The PA was correctly submitted and denied on the clinical criteria, and the prescriber has no incorrect, updated, or additional information to resubmit
• The full code-65 message confirms an ineligible plan arrangement and no eligible standalone PDP route applies
• CMS confirms that a drug included in its 2026 Part D GLP-1 utilization review was received through Part D and blocks Bridge access
• The requested product is outside the Bridge and the prescriber does not choose a covered alternative
• The current prescriber or pharmacy is blocked and you cannot obtain an eligible replacement in an acceptable timeframe
• You have decided, with your eyes open, that you are done with the process

What quitting a fixable 28-day injection route can cost

That is a $3,887 difference between 13 Bridge fills and 13 standard-price Wegovy pen fills.

The Zepbound row is a price illustration, not a promise that one program will apply the $449 price to all 13 fills in a calendar year. The current KwikPen self-pay card limits card use to 11 fills per calendar year, while Lilly's separate Journey purchase-offer section does not state that same cap. Check the live program terms for the device and checkout route you use.

For 30-day tablets, 12 fills cover 360 days: the Bridge total for that horizon is $600, not $650. Neither comparison is exactly 365 days. The page's calculator separates 28-day and 30-day products and shows the covered-day horizon so it does not hide an extra fill near the end of the year.

Still not sure which color you are?
Decode my exact next step → The page tool maps your code, responsible party, official clock, and whether cash-pay comparison should unlock. No account, email, or Medicare number.

Can Medicare beneficiaries use manufacturer cash prices?

The current Wegovy self-pay terms expressly address Medicare users purchasing outside insurance, and Lilly says self-pay is available through LillyDirect regardless of insurance status, subject to the exact program's eligibility rules. That is different from a commercial copay card, which excludes government-insured patients. A self-pay purchase stays outside Medicare and other insurance, and the patient agrees not to seek reimbursement or count it toward the deductible or out-of-pocket limit. (Wegovy self-pay terms; LillyDirect pharmacy FAQ)

This is the single most valuable commercial fact we verified, and we want to show you exactly what it does—and does not—mean.

The two programs people keep mixing up

We reviewed Novo Nordisk's full Wegovy terms on August 5, 2026. The page separates two offers:

Commercial Copay Savings Offer. This is the “pay as little as $25” card. Its terms exclude people enrolled in Medicare, Medicaid, VA, DOD, TRICARE, and similar government programs with prescription coverage.

Wegovy Self-Pay Offer. This is a separate purchase route for people whose insurance does not cover Wegovy or who choose to process outside insurance. The terms expressly give instructions to people with Medicare, Part D, or Medicare Advantage drug coverage: do not request reimbursement, do not count the purchase toward insurance cost sharing, and tell the insurer the medicine was bought outside the plan if asked.

Lilly's public pharmacy FAQ says a self-pay option is available for all LillyDirect medicines regardless of insurance status, with automatic savings applied for eligible patients. The Foundayo and Zepbound self-pay programs carry their own eligibility, purchase, and refill rules. Lilly's commercial copay-card language is separate and excludes government beneficiaries.

That is the distinction. Do not use a government-excluded commercial copay card. Do not assume that exclusion automatically erases a separately published self-pay route. Read the terms for the exact program you are using.

What paying cash actually costs you beyond the price tag

Under the self-pay terms reviewed here:

• The purchase does not count toward your Part D deductible
• It does not count toward the $2,100 2026 Part D out-of-pocket cap
• You agree not to seek reimbursement from the plan
• Extra Help does not subsidize an outside-plan cash purchase
• A cash purchase cannot be turned into a Bridge paper claim or direct reimbursement request later

If you take several expensive covered prescriptions, losing Part D credit can matter. Do the annual math before you commit.

Where you genuinely are excluded

• The commercial copay savings card when its terms exclude government-insured patients
• Coupons and discount cards applied to a Bridge claim
• Extra Help on the Bridge copay
• Bridge reimbursement after an outside cash purchase

What remains unresolved

CMS clearly excludes people found to have received a drug included in its GLP-1 utilization review through Part D in calendar year 2026. CMS has not clearly explained in public guidance whether an outside-Part-D manufacturer cash purchase can affect a later Bridge eligibility determination in another way. If you intend to keep pursuing the Bridge, call 1-800-MEDICARE before paying cash and ask about your specific record.

What cash-pay options are available after a GLP-1 Bridge claim is rejected?

If the Bridge and any relevant Part D path are truly unavailable, the best cash route depends on whether you already have a willing prescriber. Manufacturer direct usually wins when you already have clinical care; Ro becomes the stronger end-to-end option when you need the prescriber, ongoing support, and medication access in one place. Sesame remains the better Bridge-rescue branch when you still want a provider who publicly says it will submit the Medicare PA.

The route table that answers the whole question

Provider-stated vs. independently cross-checked

The facts in that table come from the organizations' current public pages. “Best for” conclusions are our editorial judgment based on price structure, whether a prescriber is included, Bridge fit, and the reader's actual bottleneck.

What do the cash-pay medications actually cost?

Current published prices start at $149 per monthly supply for Wegovy tablets and Foundayo, reach $449 for Zepbound 7.5–15 mg under Journey pricing, and can rise to $699 if the Zepbound refill condition is missed. Every number below was read from the manufacturer or provider's current pricing terms on August 5, 2026—not copied from another comparison article.

Wegovy—pens and tablets

Two deadlines matter:

The $149 limited price on 4 mg tablets requires the prescription to be written and received by NovoCare Pharmacy by August 31, 2026, and shipped by September 30, 2026. Current terms define a new Wegovy-tablet patient as an eligible patient who has never filled a Wegovy tablet prescription through NovoCare Pharmacy. The published standard 4 mg price is $199.

The $199 pen offer requires the prescription to be written and received by NovoCare Pharmacy by December 31, 2026, and shipped by January 31, 2027. It applies to a maximum of the first two 28-day fills of 0.25 mg and 0.5 mg. Current terms define a new Wegovy-injection patient as an eligible patient who has never filled a Wegovy injection prescription through NovoCare Pharmacy. (NovoCare Pharmacy terms)

Zepbound—single-dose vial or KwikPen

For 7.5–15 mg, the current Journey purchase offer requires the next purchase to be completed within 45 days of delivery or receipt of the prior prescription. Lilly's current full terms list the same regular prices for the single-dose vial and KwikPen: $499 for 7.5 mg and $699 for 10, 12.5, and 15 mg when the Journey offer does not apply. (LillyDirect Zepbound; full Zepbound terms)

Lilly publishes the general Self Pay Journey purchase offer separately from the KwikPen self-pay savings card. The current KwikPen card terms cap card use at 11 prescription fills per calendar year; the general Journey purchase-offer section does not state that same calendar-year cap. Confirm which program and terms your checkout uses before treating $449 × 13 as a guaranteed one-calendar-year total.

The device still matters in practice:

• Vials require separately purchased syringes and needles
• KwikPens require separately purchased pen needles
• The Medicare Bridge covers only the KwikPen, and CMS says Bridge pen needles are not covered
• Current Lilly self-pay Journey prices apply to both the vial and KwikPen, subject to the published terms

Set a reminder well before day 45. The difference between $449 and $699 at a higher dose is $250 per fill.

Foundayo

LillyDirect currently publishes prices for all six Foundayo doses. (LillyDirect Foundayo)

What the advertised medication price does not include

• A telehealth care or membership fee, when required
• Taxes or transaction fees that may apply
• Syringes, pen needles, or other supplies when sold separately
• A Medicare Part B or other clinician cost when you use your own prescriber
• Any lab or follow-up cost not included by the care route

That is why “starts at $149” is not the same thing as “your whole treatment costs $149.”

Should you buy direct from the manufacturer or use a telehealth program?

If you already have a willing prescriber who will manage treatment, manufacturer direct is usually the cleanest low-overhead cash route because it adds no telehealth membership. If the prescriber route itself is what broke, telehealth can be the thing you are actually paying for—but the drug and care fees must be separated before you compare.

This is the decision most people are actually making, and almost nobody prices it correctly.

The number everybody forgets

You cannot buy a prescription medication from NovoCare or LillyDirect without a valid prescription. They are access and pharmacy routes, not a substitute for clinical care.

If your existing clinician will keep prescribing, you avoid a separate telehealth membership. That does not mean every visit is free: Medicare Part B cost sharing, deductibles, and provider billing can still apply. But you are not buying a second recurring care program solely to obtain the prescription.

If your office will not prescribe or manage treatment, the prescriber cost is no longer zero. That is where telehealth stops being a middleman and starts being the service you need.

The Wegovy multi-month subscription available through select telehealth partners

Novo Nordisk announced a multi-month Wegovy subscription on March 31, 2026 for eligible self-pay patients using select telehealth partners. The manufacturer-published prices are:

The manufacturer says Wegovy HD 7.2 mg was not part of the initial subscription table. It also directs patients to participating telehealth providers for eligibility and enrollment terms. (Novo Nordisk multi-month announcement)

Do not mix this table with a 13-fill calendar calculation and call it an exact annual total. Novo publishes the subscription as 3-, 6-, or 12-month pricing and directs patients to the participating platform for complete enrollment terms. Wegovy pens are 28-day supplies, so confirm how many fills and covered days the selected platform includes before comparing the subscription with a 364-day, 13-fill estimate.

The honest comparison

The part we'd rather not tell you

Ro does not beat manufacturer direct when you already have a willing prescriber, do not need bundled care, and are comparing the same medication offer. Ro adds a care membership—$39 for the first month, then $149 month-to-month or as low as $74 per month with an annual plan paid upfront. Medication is billed separately. (Ro pricing)

If your current clinician will prescribe and manage treatment, use the direct route and skip us on this one:

• NovoCare Pharmacy for Wegovy
• LillyDirect Zepbound
• LillyDirect Foundayo

But if your prescriber route has actually broken and you need the clinician, treatment plan, support, and medication access in one place, Ro can solve the part manufacturer direct does not. Ro currently publishes FDA-approved cash-pay GLP-1 options at manufacturer-matched prices, and its government-insurance page says people with Medicare, Medicare supplement coverage, or TRICARE may still qualify for certain cash-pay treatment options after provider review. (Ro government-insurance policy)

That is not a promise that every Medicare member, state, medication, or multi-month offer qualifies. It is a reason to check the live route after the Bridge Exit Status is red.

Affiliate disclosure: Weight Loss Provider Guide may earn a commission if you use the Ro link below. That does not change the price you pay or our conclusion that manufacturer direct wins when you already have a willing prescriber and do not need Ro's care layer.

Your Bridge route is genuinely closed and you need a prescriber included?
Check FDA-approved cash-pay eligibility and current pricing at Ro → (affiliate link)
Ro's care membership and medication are separate charges. A Ro-affiliated clinician decides whether treatment is appropriate, and current cash-pay eligibility varies.

What will a full year really cost you?

The honest annual number depends on whether the product is a 28-day or 30-day supply, whether a refill offer is maintained, whether a telehealth membership is required, and whether the price changes with dose. A single “monthly price × 12” formula undercounts a 364-day treatment horizon for 28-day injections.

The 28-day vs. 30-day rule

Neither row is exactly 365 days. The point is to compare products on a stated covered-day horizon instead of pretending every “month” is the same length.

Annualized medication-only examples at a stable published price

These are stable-price examples, not predictions of what your clinician will prescribe or how long you will remain at a dose. The Zepbound $449 row also assumes every fill qualifies under the exact program used; Lilly's current KwikPen self-pay card caps use at 11 prescription fills per calendar year, while its separate Journey purchase-offer section does not state that same cap. A real first-year calculator needs a fill-by-fill dose path, the exact device/program rules, and any required care fee. If you need continuous coverage through day 365, the next fill may begin near the end of the period; the calculator should show that cash-flow timing rather than hiding it.

The costs that are not in the medication headline

Needles and syringes. Vials and KwikPens require separately purchased supplies. CMS specifically says Zepbound KwikPen needles are not covered by the Bridge. Pharmacy prices vary, so this page does not invent a universal monthly supply budget.

The care fee can be a separate bill. Ro separates membership from medication. Sesame separates its membership from the approved $50 Bridge copay. Check the exact route rather than assuming “from $39” or “from $59” includes the drug.

Dose changes. Wegovy, Zepbound, and Foundayo prices can change by dose or offer. A month-one starting price is not automatically the maintenance price.

The extra 28-day fill. Twelve 28-day boxes cover 336 days. Thirteen cover 364. A “monthly price × 12” headline misses one fill when you are comparing nearly a full year of continuous 28-day supplies.

Lost Part D credit. Outside-plan self-pay purchases and Bridge copays do not move you toward the Part D out-of-pocket cap.

Want your real number instead of a range?
Calculate my 12-month cost → Pick the product, dose path, supply length, and care route. The tool should show 28-day and 30-day horizons, offer deadlines, refill conditions, care fees, program-specific fill limits, and the cash timing of any fill that begins near the end of a 365-day period.

Should you switch medications because the Bridge rejected the claim?

A reject code is an administrative signal, not a clinical reason to switch treatment. Code 70 may mean the exact product or NDC is not Bridge-eligible, but the prescribing clinician—not a pharmacy message or affiliate page—decides whether an eligible formulation, another medication, or no change is appropriate.

The distinction matters most with Zepbound:

• The Bridge covers Zepbound KwikPen
• It does not cover the single-dose vial or single-dose pen
• Current Lilly self-pay terms include both the vial and KwikPen
• Switching from one covered Bridge GLP-1 to a different covered Bridge GLP-1 requires a new PA
• Dose changes on the same approved covered drug do not require a new PA through December 31, 2027

Do not stop, start, change dose, or change medication because of this page. Use the code to identify the administrative problem, then take the clinical decision back to the prescriber.

Are compounded GLP-1s a good backup after a Bridge rejection?

Compounded GLP-1 drugs are not Bridge-covered products and are not FDA-approved versions of Wegovy, Zepbound, or Foundayo. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing in the same way it reviews an approved finished drug product. (FDA warning-letter announcement; FDA statement on non-approved GLP-1 marketing)

We're not going to pretend this option does not exist. People do use compounded prescriptions, and cash prices can be lower.

But we will not recommend a compounded provider on this Bridge-rejection page, for three reasons we can defend.

One. You came here because a prescriber selected a specific FDA-approved medication and an administrative claim failed. A rejected claim is not permission for an affiliate page to switch you into a different regulatory category. That decision belongs with your clinician.

Two. A compounded product is not the brand and cannot be marketed as the same, a generic version, made with the same active ingredient, or clinically proven merely because the marketer wants an easier comparison. In March 2026, the FDA announced warning letters to 30 telehealth companies over false or misleading compounded GLP-1 marketing. The FDA also stated that marketers cannot make those equivalence claims.

Three. A compounded cash purchase does not solve the original Bridge claim, does not convert into a Bridge-covered product, and should not be assumed to count toward Part D spending or receive Part D reimbursement. Ask the Part D plan about any compound-specific coverage question rather than relying on a blanket affiliate claim.

If your clinician determines that a compounded prescription is medically appropriate for a patient-specific need, that is a separate clinical route. Start with how to get GLP-1 medication safely online so you know which questions to ask.

Who should not pay cash yet?

If you have not confirmed the reject code, the full message, the payer route, and the PA status, cash pay can cost thousands over a year for a problem that still has a defined fix. Read this list. If you are on it, make the next call before you open a cash-pay checkout.

You got code 75 and the handoff window is still open. That is the PA trigger. Confirm transmission and give the pharmacy-to-prescriber step up to 72 hours.

Your prescriber never received the request. After 72 hours, the prescribing clinician can download and submit the CMS form once the denied Bridge pharmacy claim exists. → Bridge paperwork guide

You got code 65 and do not have the full message. Six different CMS messages sit behind that code. Get the one that applies to you.

You got code 70. That is an NDC/product problem, not a clinical verdict. Ask whether the product or prescription must be corrected.

You have type 2 diabetes, moderate-to-severe sleep apnea, qualifying MASH, or a cardiovascular-risk prescription. The request may belong in Part D, where coverage is plan-specific and appeal rights remain. → GLP-1 prior-authorization guide

Your refill was too soon. Ask for the exact rerun date. CMS says code-79 claims can be resubmitted after more than 75% of the days-supply period has elapsed.

You are leaving town. The Bridge has a pharmacy point-of-sale vacation-fill override using submission clarification code 003. Ask the pharmacist before paying cash for an early fill.

The medication was lost or stolen. CMS says the central processor does not provide a lost-or-stolen override. Contact the prescriber and pharmacy about safe continuity options before buying or changing anything. (CMS pharmacy fill rules)

You use Medicaid rather than an eligible Medicare Part D arrangement. The Bridge rules on this page do not establish your state Medicaid coverage. → GLP-1 providers that accept Medicaid

You cannot afford any of these routes. Start with 1-800-MEDICARE, a free SHIP counselor, and the manufacturer's current assistance information before a recurring telehealth commitment.

Somewhere in the middle and not sure?
Decode my Bridge rejection → Use the exact code and timing first. After the current claim status is clear, the free matching quiz can help compare the broader GLP-1 access paths.

What we actually verified

We think you should be able to check our work—and know where we stopped. This box separates current primary-source facts from editorial conclusions and unresolved questions.

What we read directly on August 5, 2026

• CMS's Medicare GLP-1 Bridge Pharmacy NCPDP Reject Code Tool, including every code and resolution used in the decoder
• CMS's information pages for providers, pharmacies, and Part D plans
• The official Medicare GLP-1 Bridge Prior Authorization Request Form
• CMS's prescriber process, 24–72-hour transmission guidance, 72-hour decision rule, no-appeal rule, prescriber-enrollment rule, and call-center information
• CMS's current covered-product list, NDCs, fill limits, vacation override, lost/stolen rule, BIN/PCN, pharmacy help desk, and $50 cost-sharing rules
• Medicare's $2,100 Part D out-of-pocket cap for 2026
• NovoCare's current Wegovy self-pay terms, including Medicare instructions, prices, new-patient definitions, 28/30-day supply definitions, and offer deadlines
• Novo Nordisk's March 31, 2026 multi-month Wegovy subscription announcement and published tier prices
• LillyDirect's current Foundayo dose prices and 45-day terms
• Lilly's current Zepbound Self Pay Journey terms for both vials and KwikPens, including regular prices after the Journey condition is missed
• Sesame's Medicare-specific page stating that the provider confirms Medicare coverage and submits the PA, with membership starting at $59 per month
• Ro's current pricing page, government-insurance page, membership structure, and manufacturer-matched cash-price statement
• The FDA's March 3, 2026 announcement of 30 telehealth warning letters and February 6, 2026 statement on prohibited compounded-product equivalence claims
• Public Medicare Rights Center and Reddit discussions for process language only, never for medical, regulatory, eligibility, or pricing claims

What we could not confirm—and what you should verify before committing

• Whether your exact Medicare record qualifies. Only CMS and the prescribing clinician can determine that through the Bridge process.
• Whether an outside-Part-D cash fill affects a later Bridge determination in any way not addressed by current public CMS guidance. Call 1-800-MEDICARE before paying cash if you intend to keep pursuing the Bridge.
• Whether a Medicare beneficiary qualifies for a specific Wegovy multi-month telehealth subscription. The manufacturer describes it for eligible self-pay patients and directs users to participating platforms for enrollment terms.
• Live checkout totals. Taxes, fees, supplies, pharmacy availability, state availability, and plan choices can change the final amount.
• Your dose path. A licensed clinician—not this calculator—decides what is medically appropriate.
• Any provider's future pricing or policy. Current terms can be modified or ended.

What we did not do

We did not submit a test claim, pose as a patient, access a medical record, or manufacture a “success story.” We did not determine anyone's clinical eligibility. We did not treat provider marketing as proof when a CMS, Medicare, FDA, or manufacturer primary source was available.

Prices and program terms change. This page shows the date we last checked, and the commercial facts should be rechecked monthly while the Bridge is new.

How did we build the Bridge rejection and cash-pay matrix?

The official code meaning comes from CMS; the patient-facing owner map, call scripts, Bridge Exit Status, and route comparison are original Weight Loss Provider Guide editorial work. We built the page to answer the question CMS's pharmacy document does not: Who owns my next move, what do I say, how long do I wait, and when is cash pay actually rational?

Source hierarchy

1. CMS and Medicare.gov for Bridge, Part D, eligibility, claim-processing, timing, cost-sharing, and appeal facts
2. FDA and approved-product sources for approval and compounding distinctions
3. Manufacturer terms for medication price, offer eligibility, refill conditions, and supply definitions
4. Provider pages for membership, workflow, product menu, and provider-stated services
5. Public comments and forums only to capture the words people use for administrative confusion

Fact categories

Medical and regulatory facts include FDA status, covered products, eligibility rules, Part D routing, and compounding distinctions. They require government or approved-product sources.

Verified commercial facts include current prices, membership fees, offer deadlines, refill conditions, and provider-published workflow. They require a current manufacturer or provider source and a verification date.

Editorial conclusions include green/amber/red status, “best for” routing, and when a paid care layer is worth it. Those conclusions are labeled as ours and flow from the verified facts above.

What is original here

The page does not claim ownership of CMS's reject codes. Its original asset is the assembled dataset:

Reject code → full meaning → responsible party → exact call script → official clock → Bridge Exit Status → cash-pay unlock → all-in cost structure

No single source we reviewed gives a beneficiary that complete chain in one place.

Frequently asked questions

The questions below close the remaining gaps that most often send people back to search: code 75, Part D routing, code 65, code 70, PA timing, appeals, refill limits, cash-pay eligibility, and what happens after a cash fill. Each answer follows the same primary-source rules used in the decoder and price tables.

Is code 75 a denial?

No. Code 75 means prior authorization is required. The official PA form requires a denied Bridge pharmacy claim before the prescribing clinician submits the PA. Approval still depends on the completed clinical form.

Does every first Bridge claim reject with code 75?

No. A correctly routed claim that needs prior authorization may return code 75, but other first claims can return identity, product, quantity, timing, plan, or technical codes. Get the exact code and full message.

Do I need a Part D denial before using the Bridge?

No. CMS says a Part D denial is not required first. A potentially eligible weight-management claim can be directed straight to the Bridge central processor.

Why does Humana appear if Humana is not my Part D plan?

CMS uses Humana as the Bridge central processor for prior authorization, claim adjudication, and pharmacy payment. Confirm that the communication concerns the Medicare GLP-1 Bridge and read the stated reason.

How do I find my reject code?

Ask the pharmacy for the exact NCPDP reject code and the full message attached to it. Also ask which payer received the claim and which BIN and PCN were used.

Does code 70 mean I failed the health requirements?

No. Code 70 means the submitted NDC is not eligible for the Bridge. CMS directs the claim toward an eligible NDC when appropriate. The prescriber must decide whether the prescription should be corrected.

What if my prescriber never received the PA request?

After 72 hours, the prescribing clinician can download and submit the CMS form once the denied Bridge pharmacy claim exists. The office should check both its electronic PA queue and fax inbox first.

Can the pharmacist submit the Bridge PA for me?

The pharmacy transmits the PA request. The prescribing clinician completes and submits the clinical prior authorization.

How long does a Bridge PA decision take?

CMS says the approval or denial is sent to the prescriber by ePA or fax and mailed to the patient within 72 hours of submission. Paper delivery to the patient may take longer than the transmission to the prescriber.

What if the PA is approved but the pharmacy still says rejected?

Ask the pharmacy to rerun the Bridge claim. CMS says pharmacies without an ePA notification may need to resubmit the claim after approval.

Can I appeal a Bridge denial?

There is no formal Bridge appeal. The prescribing clinician may resubmit when the original form contained incorrect information or when updated or additional information is available. Part D appeal rights remain separate.

Can any doctor submit the Bridge paperwork?

A prescribing clinician can submit it. CMS says the provider does not need to be enrolled in Medicare, but the provider must not be on the CMS Preclusion List.

Does a dose change require another PA?

No, not while remaining on the same covered GLP-1 under an approved Bridge PA. Switching to a different covered GLP-1 requires a new PA.

Can I get a 90-day Bridge supply?

No. The Bridge provides one 28-day or 30-day monthly supply per fill. Sixty-day, 90-day, partial, and transition fills are not available.

Can I get an early fill for vacation?

CMS provides a pharmacy point-of-sale vacation override using submission clarification code 003. Ask the pharmacist to review the Bridge vacation-fill rule.

What happens if the medication is lost or stolen?

CMS says the central processor will not provide a lost-or-stolen override. Contact the prescriber and pharmacy about safe next steps.

Does the $50 copay count toward my Part D out-of-pocket cap?

No. The Bridge operates outside Part D, so the $50 does not count toward the deductible or the $2,100 Part D out-of-pocket cap for 2026.

Can Extra Help reduce the $50?

No. CMS says the Part D low-income subsidy does not apply to the Bridge copay.

Can Medicare beneficiaries use NovoCare or LillyDirect self-pay prices?

The current manufacturer materials separate government-excluded commercial copay cards from self-pay purchase programs. Wegovy's self-pay terms expressly address Medicare users purchasing outside insurance. Lilly says self-pay is available through LillyDirect regardless of insurance status, with program-specific eligibility rules. Confirm the exact current terms before each purchase.

Can I pay cash while the PA is pending?

You can ask the pharmacy and prescriber about an outside-insurance cash fill, but understand the tradeoff: the purchase can cost hundreds more, does not count toward Part D spending under the self-pay terms, cannot be submitted to the Bridge for reimbursement, and may complicate an active prescription workflow. Call 1-800-MEDICARE before paying if you intend to keep pursuing the Bridge.

Will paying cash now make me ineligible for the Bridge later?

Current public CMS guidance clearly addresses drugs included in its GLP-1 utilization review and received through Part D in 2026, but it does not clearly answer every interaction with an outside-Part-D cash fill. We will not guess. Call 1-800-MEDICARE about your specific record before paying cash.

Are Ozempic or Mounjaro covered by the Bridge?

No. The current Bridge list is Foundayo, Wegovy injections and tablets, and Zepbound KwikPen. Ozempic and Mounjaro may be relevant to ordinary Part D for an approved diabetes use, which is a separate route.

Are compounded semaglutide or tirzepatide covered by the Bridge?

No. Compounded products are not on the current Bridge covered-product list and are not FDA-approved versions of the named brands.

When does the Medicare GLP-1 Bridge end?

The current program runs through December 31, 2027. CMS extended it after delaying the Part D portion of the follow-on BALANCE model. (CMS provider FAQ)

Why does the page use $650 for an injection horizon but $600 for a tablet horizon?

Bridge injections are generally 28-day fills, so 13 fills cover 364 days. The tablets are 30-day fills, so 12 fills cover 360 days. Calling both “$50 a month” without showing the supply length hides a real difference. Neither row is exactly 365 days.

Does the Bridge reimburse me if I pay cash first?

No. CMS says the central processor accepts electronic pharmacy claims and does not accept paper claims or direct member reimbursement requests.

One last thing

A rejected claim feels like a door closing. In this program, code 75 can be the door opening—the system just phrased it terribly.

So: get the code. Get the full message. Confirm the payer. Work the correct clock.

And if the Bridge really is a dead end, you now know which manufacturer self-pay terms allow an outside-insurance purchase, which prices expire or depend on refill timing, when a telehealth membership adds real value, and when it is just an extra bill. That is a decision you can make with your eyes open, which is the only kind worth making.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We may earn a commission when readers use certain provider links. We do not earn anything from Medicare, CMS, NovoCare, or LillyDirect—and those routes win when they are the better answer.

This article is general information, not medical advice. It does not diagnose Bridge eligibility or recommend a medication or dose. Only a licensed prescriber can decide what treatment is appropriate, and CMS determines Bridge coverage through its process.

Last verified: August 5, 2026 · Next scheduled review: September 5, 2026

Sources

The sources below are the primary government, manufacturer, and provider pages used for the material claims on this page. Public comments are included only for voice-of-customer language and are not used to prove eligibility, pricing, safety, or medical outcomes.

1. CMS — Medicare GLP-1 Bridge Pharmacy NCPDP Reject Code Tool
2. CMS — Information for Providers
3. CMS — Information for Pharmacies
4. CMS — Information for Part D Plans
5. CMS — Medicare GLP-1 Bridge Prior Authorization Request Form
6. Medicare — 2026 Part D Costs
7. NovoCare — Wegovy Commercial and Self-Pay Offer Terms
8. NovoCare Pharmacy — Current Wegovy Prices and Program Terms
9. Novo Nordisk — March 31, 2026 Wegovy Multi-Month Subscription Announcement
10. LillyDirect — Zepbound
11. Lilly — Zepbound Full Terms and Conditions
12. LillyDirect — Foundayo
13. LillyDirect — Pharmacy FAQ
14. Sesame — Medicare Weight-Loss Program
15. Ro — Weight-Loss Program Pricing
16. Ro — Government Insurance and Cash-Pay Eligibility
17. FDA — Warning Letters to 30 Telehealth Companies, March 3, 2026
18. FDA — February 6, 2026 Statement on Non-FDA-Approved GLP-1 Marketing
19. Medicare Rights Center — Public Bridge Program Discussion
20. Reddit r/medicare — “provider never gets a PA” discussion
21. Reddit r/medicare — claim sent to Part D instead of the Bridge
22. SHIP — Free Medicare Counseling